Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
HPB (Oxford). 2021 Apr;23(4):483-494. doi: 10.1016/j.hpb.2020.11.008. Epub 2020 Dec 4.
Contemporary practice for superior mesenteric/portal vein (SMV-PV) reconstruction during pancreatectomy with vein resection involves biological (autograft, allograft, xenograft) or synthetic grafts as a conduit or patch. The aim of this study was to systematically review the safety and feasibility of the different grafts used for SMV-PV reconstruction.
A systematic search was performed in PubMed and Embase according to the PRISMA guidelines (January 2000-March 2020). Studies reporting on ≥ 5 patients undergoing reconstruction of the SMV-PV with grafts during pancreatectomy were included. Primary outcome was rate of graft thrombosis.
Thirty-four studies with 603 patients were included. Four graft types were identified (autologous vein, autologous parietal peritoneum/falciform ligament, allogeneic cadaveric vein/artery, synthetic grafts). Early and overall graft thrombosis rate was 7.5% and 22.2% for synthetic graft, 5.6% and 11.7% for autologous vein graft, 6.7% and 8.9% for autologous parietal peritoneum/falciform ligament, and 2.5% and 6.2% for allograft. Donor site complications were reported for harvesting of the femoral, saphenous, and external iliac vein. No cases of graft infection were reported for synthetic grafts.
In selected patients, autologous, allogenic or synthetic grafts for SMV-PV reconstruction are safe and feasible. Synthetic grafts seems to have a higher incidence of graft thrombosis.
在伴有静脉切除的胰切除术期间,进行肠系膜上静脉/门静脉(SMV-PV)重建的当代实践涉及生物(自体移植物、同种异体移植物、异种移植物)或合成移植物作为导管或补丁。本研究的目的是系统地回顾用于 SMV-PV 重建的不同移植物的安全性和可行性。
根据 PRISMA 指南(2000 年 1 月至 2020 年 3 月)在 PubMed 和 Embase 中进行了系统搜索。纳入了报道在胰切除术期间使用移植物进行 SMV-PV 重建的≥5 例患者的研究。主要结局是移植物血栓形成率。
纳入了 34 项研究共 603 例患者。确定了四种移植物类型(自体静脉、自体壁层腹膜/镰状韧带、同种异体尸体静脉/动脉、合成移植物)。合成移植物的早期和总体移植物血栓形成率分别为 7.5%和 22.2%,自体静脉移植物分别为 5.6%和 11.7%,自体壁层腹膜/镰状韧带分别为 6.7%和 8.9%,同种异体移植物分别为 2.5%和 6.2%。报道了采集股、隐静脉和髂外静脉时的供体部位并发症。未报告合成移植物的移植物感染病例。
在选择的患者中,SMV-PV 重建用自体、同种异体或合成移植物是安全且可行的。合成移植物似乎有更高的移植物血栓形成发生率。